Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

enues under the Company's elagolix collaboration agreement. Revenues for the year ended December 31, 2012 were $53.1 million, compared with $77.4 million for 2011. The $24.3 million decrease in revenue is primarily due to $30 million in milestones achieved under the Company's elagolix collaboration agreement during the third quarter of 2011.

Research and development expenses increased to $9.1 million during the fourth quarter of 2012 compared with $8.0 million for the same period in 2011. For the year ended December 31, 2012, research and development expenses were $37.2 million, compared to $31.0 million for 2011. The increase in research and development expenses is primarily driven by Phase IIb development expenses for the VMAT2 program, coupled with increased compensation related costs, primarily due to equity based compensation.

General and administrative expenses increased to $3.3 million during the fourth quarter of 2012 compared with $2.7 million for the same period last year. For the year ended December 31, 2012, general and administrative expenses were $13.4 million, compared to $12.5 million for 2011. The increase in year-to-date general and administrative expenses is primarily related to higher equity based compensation costs.

2013 Financial GuidanceThe Company expects to have a net cash burn from operations of approximately $50 to $55 million in 2013. Revenue is expected to approximate $3 million which consists solely of the amortization of up-front license fees. Expenses for 2013 should approximate $55 to $60 million. Net loss for 2013 is expected to be $50 to $55 million, or $0.75 to $0.83 loss per share based on 66.5 million basic shares outstanding. The Company expects to end 2013 with in excess of $130 million in cash, investments and receivables.

Pipeline HighlightsElagolix UpdateAbbVie is currently conducting the initial Phase III study of elagolix for endometriosis, the Violet Petal Study. The study is a 24-week
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... 19, 2014 The “Human Insulin ... Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, ... NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018” ... restraints, challenges, opportunities, current market trends, and strategies ... the estimates and forecasts of the revenue and ...
(Date:10/18/2014)... 18, 2014 The Asian arthroscopic devices ... with analysis and forecast of revenue. The arthroscopic devices ... million by 2018, at a CAGR of 6.5% from ... the Asian arthroscopic devices market, to get an idea ... glimpse of the segmentation of arthroscopic devices market in ...
(Date:10/18/2014)... The Asian Electronic Medical Record (EMR) market report defines and ... of revenue. The electronic medical record market in the Asian ... at a CAGR of 9.4% from 2013 to 2018. , ... (EMR) market, to get an idea of the in-depth analysis ... the market in the same region, and is supported by ...
(Date:10/18/2014)... 2014 The report " Cloud ... Text; Web; Speech; Machine; Video; Predictive Analytics: Global ... Forecasts & Analysis (2013 - 2018) ", defines ... various sub segments with an in-depth analysis and ... the factors driving this market, various restraints, and ...
Breaking Biology Technology:Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 2The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 3The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 2The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 5Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 2Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 4Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 5
... 9 Insmed Inc. (Nasdaq:,INSM), a developer of follow-on ... Therapeutics, will present at the,Collins Stewart Fourth Annual Growth ... in New York., The conference will take place ... Tuesday, July 8 through Thursday, July 10. Insmed,s,presentation will ...
... Inc.,(OTC Bulletin Board: CAGC) ("China Agritech" or "the ... today announced that it,has entered into a contract ... Ezz,Group, a distributor of agricultural and fertilizer products ... Group began working with China Agritech over a ...
... MARINO, Calif., July 9 Epeius Biotechnologies,Corporation today ... by the U.S. Food and Drug Administration (FDA) ... latest approval is the third,clinical indication for which ... the United States. This latest approval for Rexin-G ...
Cached Biology Technology:Insmed to Present at Collins Stewart Fourth Annual Growth Conference 2China Agritech to Export Products to Egypt 2China Agritech to Export Products to Egypt 3FDA Grants Epeius Biotechnologies' Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas 2FDA Grants Epeius Biotechnologies' Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas 3
(Date:10/14/2014)... 14, 2014 – High doses of fish oil supplements, rich ... common type of irregular heartbeat in which the heart can ... of the AFFORD trial led by the Montreal Heart Institute ... of Cardiology on October 7th. , For the trial, ... were randomly assigned to 4 grams of fish oil a ...
(Date:10/14/2014)... international team of researchers, led by the Chinese Academy ... Nature Genetics a brief genomic history of ... the tomato plant. , The C.M. Rick Tomato Genetics ... in this study by providing seed of both cultivated ... which builds on the first tomato genome sequence completed ...
(Date:10/14/2014)... 14 October 2014 – Researchers from Stanford University School ... mechanism used by cells and the activation of muscle ... blocks" and generate energy during times of nutrient deprivation. ... that when this protective mechanism is operational it also ... "Our study reveals that when stem cells emerge from ...
Breaking Biology News(10 mins):Autophagy helps fast track stem cell activation 2
... may trigger a new mass extinction event, where over 50 ... out, warn scientists at the Universities of York and Leeds. ... discovered a close association between Earth climate and extinctions in ... 520 million years almost the entire fossil record available. ...
... that viruses may contribute to cancer by causing excessive death ... with cancerous traits. Viruses may act as forces of natural ... of viruses and leaving behind those cells that have acquired ... and over, cancer can develop say study authors, led by ...
... Jones, a fisheries oceanographer at the Cooperative Institute for Marine ... Rosenstiel School, set out to design a better light trap ... would contribute to the discovery of a new species. But, ... description, his catch turned out to be the answer to ...
Cached Biology News:Fossil record supports evidence of impending mass extinction 2Study proposes new theory of how viruses may contribute to cancer 2New light trap captures larval stage of new species; DNA barcode technology used 2
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... technology, SilenceMag is the most efficient ... and easy to use, SilenceMag is ... designed for siRNA delivery, SilenceMag allows ... doses of siRNA.,SilenceMag formulation gives reliable ...
... is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
Biology Products: